1. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency;Regnstrom;Eur J Clin Pharmacol,2010
2. The added value of patient engagement in early dialogue at EMA: scientific advice as a case study;Murphy;Front Med (Lausanne),2021
3. European Commission, European Medicines Agency, Heads of Medicines Agencies. Scientific Advice on Medicines for Human Use in the EU Medicines Regulatory Network. Mapped Information on Current Voluntary Procedures [Europa website]. 2022. Available at: https://accelerating-clinical-trials.europa.eu/priority-action-areas/scientific-advice_en. Accessed November 12, 2023.
4. Clinical Trials Facilitation and Coordination Group. Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials [HMA website]. 2019. Available at: https://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2019_02_CTFG_Recommendation_paper_on_Complex_Clinical_Trials.pdf. Accessed April 19, 2023.
5. European Medicines Agency. PRIME: Priority Medicines [EMA website]. Available at: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines. Accessed July 6, 2023.